With the American Heart Association’s 2018 Scientific Sessions set for Nov. 10-12 in Chicago, two co-chairs of the programming committee previewed the themes of the meeting, its most anticipated clinical trials and the two new guidelines that will be unveiled.

ScieGen Pharmaceuticals has issued a recall of the blood pressure drug irbesartan after lab testing revealed a carcinogenic impurity, the FDA announced in a MedWatch Safety Alert.

A study out of Binghamton University in New York suggests heart rate (HR) and blood pressure (BP) respond to environmental demands by undergoing allostasis rather than homeostasis, adding further evidence to a hypothesis scientists have mulled for years.

Another drug with the potential to lower cholesterol beyond maximally tolerated statin therapy is preparing to enter the marketplace, STAT reported on Oct. 28.

A new study published in the European Journal of Preventive Cardiology identified a strong link between vitamin D levels in the blood and cardiorespiratory fitness (CRF)—with individuals in the top quartile of vitamin D being almost three times more fit than those in the bottom quartile after adjustment for clinical characteristics.

Low blood pressure (BP) and weight loss could signal an impending diagnosis of dementia, while elevated blood glucose levels may represent a consistent risk factor for the condition, according to a 14-year study published in the October issue of JAMA Psychiatry.

Figures released by England’s National Health Service have revealed that around 500 U.K. residents die prematurely each week from complications of diabetes, including amputations, CVD, stroke and kidney disease.

The FDA has approved canagliflozin (Invokana) to reduce the risk of major adverse cardiovascular events (MACE) including stroke, heart attack and cardiac death in patients with type 2 diabetes and established cardiovascular disease. It is the first oral diabetes medication to gain this indication, according to drug manufacturer Janssen Pharmaceutical Companies.